IFF (NYSE: IFF) reported Q1 EPS of $1.20, $0.07 better than the analyst estimate of $1.13. Revenue for the quarter came in at $2.8 billion versus the consensus estimate of $2.83 billion.

GUIDANCE:

IFF sees FY2025 revenue of $10.6-10.9 billion, versus the consensus of $10.859 billion.

Full year 2025 adjusted operating EBITDA to be in the range of $2 billion to $2.15 billion. This outlook includes the impact of current tariff exposure and does not account for potential recessionary pressures that could arise from recent shifts in trade policy.

The Company continues to expect comparable currency neutral sales growth to be between 1% to 4%, with growth in most businesses. Comparable currency neutral adjusted operating EBITDA is expected to grow 5% to 10% year-over-year.

Based on recent market foreign exchange rates, the Company now expects that foreign exchange will have an approximately 2% (versus 4% previously) adverse impact to sales growth and an approximately 3% (versus 6% previously) adverse impact to adjusted operating EBITDA growth in 2025.

Full year guidance now includes four months of Pharma Solutions results (versus six months previously) as the divestiture closed earlier-than-anticipated on May 1, 2025. This results in an approximately 7% (versus 5% previously) adverse impact to sales growth and an approximately 8% (versus 6% previously) adverse impact to adjusted operating EBITDA growth in 2025.

The Company cannot reconcile its expected adjusted operating EBITDA without unreason

For earnings history and earnings-related data on IFF (IFF) click here.